RecruitingNCT06031727
CRISPR/cas13-medIated RNA TarGeting THerapy for the Treatment of Neovascular Age-related Macular Degeneration Investigator-initiated Trial (SIGHT-I)
EARLY_PHASE1 · 12 planned enrolment
- Countries listed
- 1
- Registry update
- March 17, 2025
